Who
Christopher J. Schaber
Chairman, CEO and President
Company insider
Files Form 4 as: Chairman, CEO and President, Soligenix; Exec. VP & COO, Windtree Therapeutics.
In numbers
- Trades disclosed
- 64
- Buys
- 16
- Sells
- 0
- Bought
- $307K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 21 Jul 2005
- Last trade
- 12 Oct 2026
- Last filed
- 13 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Oct 2026filed 13 Oct 2026 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code D | —250 at $0.00 | filing |
| 12 Oct 2026filed 13 Oct 2026 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code D | —197 at $0.00 | filing |
| 12 Oct 2026filed 13 Oct 2026 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code D | —583 at $0.00 | filing |
| 12 Oct 2026filed 13 Oct 2026 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code D | —250 at $0.00 | filing |
| 12 Oct 2026filed 13 Oct 2026 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code D | —250 at $0.00 | filing |
| 12 Oct 2026filed 13 Oct 2026 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code D | —250 at $0.00 | filing |
| 12 Oct 2026filed 13 Oct 2026 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code D | —250 at $0.00 | filing |
| 12 Oct 2026filed 13 Oct 2026 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code D | —250 at $0.00 | filing |
| 12 Oct 2026filed 13 Oct 2026 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code D | —250 at $0.00 | filing |
| 12 Oct 2026filed 13 Oct 2026 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code D | —250 at $0.00 | filing |
| 12 Oct 2026filed 13 Oct 2026 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code D | —52 at $0.00 | filing |
| 11 Dec 2025filed 12 Dec 2025 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 2 Oct 2025filed 3 Oct 2025 | SNGX SoligenixBiotechnology | SEC FORM 4 Bought | $20K15,132 at $1.32 | filing |
| 12 Dec 2024filed 13 Dec 2024 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 8 Dec 2023filed 8 Dec 2023 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 8 Dec 2022filed 9 Dec 2022 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code A | —140,000 at $0.00 | filing |
| 18 May 2022filed 18 May 2022 | SNGX SoligenixBiotechnology | SEC FORM 4 Bought | $8,80020,000 at $0.44 | filing |
| 21 Jan 2022filed 21 Jan 2022 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code A | —47,315 at $0.00 | filing |
| 3 Jan 2022filed 4 Jan 2022 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 17 Dec 2021filed 20 Dec 2021 | SNGX SoligenixBiotechnology | SEC FORM 4 Bought | $5,1807,000 at $0.74 | filing |
News
Reviewing Soligenix (NASDAQ:SNGX) and Curis (NASDAQ:CRIS)SNGX · themarketsdaily.com · 17 Oct 2026
0 headlines in the last 90 days name Christopher J. Schaber; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.